Vertex Pharmaceuticals (NASDAQ:VRTX) Issues Quarterly Earnings Results

Vertex Pharmaceuticals (NASDAQ:VRTX) posted its quarterly earnings results on Monday. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01), FiscalAI reports. The firm had revenue of $3.33 billion for the quarter, compared to the consensus estimate of $3.23 billion. Vertex Pharmaceuticals had a return on equity of 23.66% and a net margin of 35.00%.The business’s revenue was up 12.5% compared to the same quarter last year. During the same period last year, the company posted $4.52 earnings per share.

Here are the key takeaways from Vertex Pharmaceuticals’ conference call:

• Positive Sentiment: Vertex reported second-quarter revenue of $3.3 billion, up 12% year over year, and raised 2026 revenue guidance to $13.1 billion–$13.2 billion. Management maintained its target of at least $500 million in non-CF revenue, while expecting operating expenses near the high end of its $5.65 billion–$5.75 billion range.
• Positive Sentiment: The cystic fibrosis franchise remained strong, with global revenue up 11% and ALYFTREK exceeding $1 billion in first-half revenue. Vertex highlighted rapid ALYFTREK adoption, including more than one-third of eligible patients in Germany and the U.K., and is pursuing additional approvals in younger children and rare mutations.
• Positive Sentiment: CASGEVY revenue rose to $76 million in the second quarter, up roughly 75% sequentially, while JOURNAVX revenue reached $50 million, up about 70% sequentially. CASGEVY patient initiations and infusions continued to build, and JOURNAVX prescriptions, prescriber adoption, hospital pathways, and payer coverage expanded significantly.
• Negative Sentiment: JOURNAVX’s rapid prescription growth is increasing use of Vertex’s patient support program because of remaining payer restrictions, delaying gross-to-net normalization until the first half of 2027. Management also cautioned that quarterly revenue may remain volatile as channel inventory and reimbursement patterns normalize.
• Positive Sentiment: Vertex is preparing for a potential November 30 FDA decision on povetacicept in IgA nephropathy, citing strong efficacy, monthly at-home auto-injector dosing, and a favorable safety profile. The company also advanced multiple pipeline programs, including completion of enrollment in studies of inaxaplin and VX-407, an upcoming type O islet-cell therapy trial, and the planned acquisition of Crinetics to establish a rare-endocrine franchise.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $478.70 on Wednesday. The firm has a 50-day moving average of $472.20 and a 200-day moving average of $460.65. Vertex Pharmaceuticals has a 52-week low of $362.50 and a 52-week high of $533.67. The stock has a market cap of $121.49 billion, a PE ratio of 28.39, a PEG ratio of 2.12 and a beta of 0.30.

Analysts Set New Price Targets

A number of equities analysts recently commented on VRTX shares. Weiss Ratings upgraded Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, July 17th. Barclays reiterated an “overweight” rating and set a $617.00 target price on shares of Vertex Pharmaceuticals in a research note on Wednesday. TD Cowen boosted their target price on Vertex Pharmaceuticals from $525.00 to $550.00 and gave the stock a “buy” rating in a report on Tuesday. Sanford C. Bernstein upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. Finally, Morgan Stanley lifted their price objective on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $562.52.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 1,500 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total transaction of $787,485.00. Following the completion of the sale, the executive vice president owned 45,321 shares of the company’s stock, valued at $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 6,988 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $3,144,600.00. Following the completion of the transaction, the chief marketing officer directly owned 26,088 shares in the company, valued at approximately $11,739,600. This represents a 21.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 17,452 shares of company stock valued at $8,103,997 over the last quarter. 0.20% of the stock is owned by corporate insiders.

Institutional Trading of Vertex Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership increased its holdings in Vertex Pharmaceuticals by 520.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 381,195 shares of the pharmaceutical company’s stock valued at $149,291,000 after purchasing an additional 319,725 shares during the period. Man Group plc boosted its holdings in Vertex Pharmaceuticals by 184.3% in the third quarter. Man Group plc now owns 362,774 shares of the pharmaceutical company’s stock valued at $142,077,000 after acquiring an additional 235,156 shares during the last quarter. Alyeska Investment Group L.P. increased its position in Vertex Pharmaceuticals by 311.0% during the 3rd quarter. Alyeska Investment Group L.P. now owns 267,169 shares of the pharmaceutical company’s stock valued at $104,634,000 after purchasing an additional 202,169 shares during the period. Amundi increased its position in Vertex Pharmaceuticals by 16.6% during the 4th quarter. Amundi now owns 1,304,161 shares of the pharmaceutical company’s stock valued at $591,254,000 after purchasing an additional 185,190 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Vertex Pharmaceuticals by 20.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 945,660 shares of the pharmaceutical company’s stock worth $428,726,000 after purchasing an additional 162,074 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and outlook strengthened: Second-quarter revenue rose 12.5% year over year to $3.33 billion, exceeding the $3.23 billion consensus estimate. Vertex raised its 2026 revenue outlook to $13.1 billion-$13.2 billion, above the roughly $13.0 billion analyst forecast, citing continued cystic fibrosis demand and growth from CASGEVY and JOURNAVX. Vertex raises annual revenue forecast on cystic fibrosis drugs strength
• Positive Sentiment: Pipeline diversification is gaining attention: Vertex’s pending approximately $10 billion acquisition of Crinetics Pharmaceuticals is expected to add rare endocrine disease assets and support management’s strategy to build a fifth business pillar beyond cystic fibrosis. Investors are also anticipating the near-term launch of Vertex’s renal treatment and additional pipeline catalysts. Vertex buys Crinetics to push beyond cystic fibrosis
• Positive Sentiment: Analysts see further upside potential: UBS said Vertex is well positioned ahead of pipeline catalysts, while Cantor Fitzgerald raised its price target to $595 and retained an Overweight rating. RBC also characterized the quarter and raised outlook as evidence of core-business strength. Vertex Pharmaceuticals seen well positioned ahead of pipeline catalysts
• Neutral Sentiment: EPS was essentially in line but technically missed: Adjusted earnings of $4.73 per share came in just below the $4.74 consensus estimate, although earnings increased from $4.52 a year earlier. The modest miss limits the impact of the revenue beat. Why Vertex Pharmaceuticals stock ticked higher on Tuesday
• Negative Sentiment: Cystic fibrosis competition remains the key overhang: Analysts warned that upcoming clinical data from much smaller rival Sionna Therapeutics could challenge Vertex’s dominant CF franchise, making the competitor’s readout an important catalyst for VRTX. Vertex’s biggest overhang: a rival 50 times smaller
• Negative Sentiment: Valuation and analyst caution could restrain gains: Canaccord raised its target only to $442 and maintained a Hold rating, implying downside from the current level. Needham also kept a Hold rating, citing early-stage diversification and execution risks related to the Crinetics integration.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.